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Abstract
LHX3 is a LIM-homeodomain transcription factor with critical roles in pituitary and nervous
system development. Mutations in the LHX3 gene are associated with pediatric diseases featuring
severe hormone deficiencies, hearing loss, developmental delay, and other symptoms. The
mechanisms that govern LHX3/Lhx3 transcription are poorly understood. In this study, we
examined the role of DNA methylation in the expression status of the mouse Lhx3 gene. Pituitary
cells that do not normally express Lhx3 (Pit-1/0 cells) were treated with 5-aza-2’-deoxycytidine, a
demethylating reagent. This treatment lead to activation of Lhx3 gene expression suggesting that
methylation contributes to Lhx3 regulation. Treatment of Pit-1/0 pituitary cells with a combination
of a demethylating reagent and a histone deacetylase inhibitor led to rapid activation of Lhx3
expression, suggesting possible crosstalk between DNA methylation and histone modification
processes. To assess DNA methylation levels, treated and untreated Pit-1/0 genomic DNA was
subjected to bisulfite conversion and sequencing. Treated Pit-1/0 cells had decreased methylation
at specific sites in the Lhx3 locus compared to untreated cells. Chromatin immunoprecipitation
assays demonstrated interactions between the MeCp2 methyl binding protein and Lhx3 promoter
regions in the Pit-1/0 cell line. Overall, this study demonstrates that DNA methylation patterns of
the Lhx3 gene are associated with its expression status.
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1. Introduction
The LIM-homeodomain 3 (LHX3) transcription factor plays key gene regulatory roles
during pituitary gland organogenesis and nervous system development (Kelberman et al.,
2009; Davis et al., 2010; Prince et al., 2011; Mollard et al., 2012). Homozygous Lhx3
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knockout mice are not viable, do not develop the anterior and intermediate lobes of the
pituitary, fail to differentiate four of the five anterior pituitary hormone-secreting cell types,
and have impaired spinal neuron specification (Sheng et al., 1996; Sharma et al., 1998). In
the anterior pituitary, LHX3 activates the transcription of hormone subunit and transcription
factor genes, including the alpha glycoprotein subunit (αGSU), follicle-stimulating hormone
(FSHβ), prolactin (PRL), gonadotropin-releasing hormone receptor (GnRH-R), and Pit-1
genes (reviewed in Colvin et al., 2009; Prince et al., 2011).
Recessive mutations in the human LHX3 gene are associated with complex syndromes
featuring combined pituitary hormone deficiency disease (CPHD) and other symptoms
(reviewed by Pfaffle and Klammt, 2011). Patients with recessive LHX3 mutations have
deficiencies in growth hormone, PRL, thyroid-stimulating hormone, FSH, and luteinizing
hormone, with resulting short stature, metabolic defects and delayed/failed puberty
(Netchine et al., 2000; Bhangoo et al., 2006; Pfaeffle et al., 2007; Rajab et al., 2008;
Kristrom et al., 2009; Bonfig et al., 2011; Colvin et al., 2011; Bechtold-Dalla Pozza et al.,
2012). Other LHX3 mutation-associated symptoms may include abnormal pituitary gland
morphology, rigid cervical spine, hearing loss, and adrenocorticotropic hormone deficiency.
Characterized mammalian Lhx3 genes, comprising seven exons and six introns, produce two
major mRNA transcripts: Lhx3a and Lhx3b (Bach et al., 1995; Zhadanov et al., 1995; Sloop
et al., 2000; Sloop et al., 2001). The Lhx3 gene contains two TATA-less, GC-rich Lhx3a and
Lhx3b promoters containing conserved nuclear factor 1 (NF1) and specificity protein 1
(SP1) transcription factor binding sites (Yaden et al., 2006). The SOX2 developmental
transcription factor has been shown to bind and activate the human LHX3a promoter (Rajab
et al., 2008). The human LHX3 promoters are alone insufficient to guide gene expression in
vivo indicating that the actions of additional elements must be required for tissue-specific
transcriptional control of LHX3 protein expression (Mullen et al., 2012). A complex
enhancer unit located downstream of the gene has been shown to contain modular elements
conferring some aspects of pituitary and nervous system gene expression (Mullen et al.,
2012) but the mechanisms by which LHX3 expression is precisely controlled over time and
in specific cell types, including the roles of the two promoters, remain incompletely
characterized.
DNA methylation is a significant mediator of transcriptional regulation in the cell. DNA
methyltransferases (DNMTs) catalyze the addition of a methyl group to the 5′ position of the
cytosine pyrimidine ring of CpG (cytosine-phosphate bond-guanine) dinucleotides
(Ramsahoye et al., 1996; Robertson and Jones, 2000). DNA methylation has been
implicated in chromatin silencing, X chromosome inactivation, the imprinting of parental
alleles, viral gene inactivation, and silencing of specific genes during cellular determination
and differentiation (reviewed in Ramsahoye et al., 1996; Dulac, 2010). Methyl-CpG binding
proteins (MBPs) bind methylated DNA and recruit regulatory proteins to modulate
chromatin structure and gene activity (Buck-Koehntop and Defossez, 2013). The
interactions between DNA methyl-binding proteins and histone modifying proteins are
likely essential for coordinated transcriptional regulation in cells during development
(Vaissiere et al., 2008). For example, the methyl-binding protein, MeCP2 can interact with
histone methyltransferases to mediate repression (Lunyak et al., 2002; Fuks et al., 2003).
Aberrant DNA methylation, as well as alterations to methylation machinery, is associated
with many diseases (reviewed in Robertson, 2005) implicating DNA methylation as a
fundamental process in regulating gene expression.
Although large-scale “methylome” data indicates that high levels of cytosine methylation
occur at CpG-poor DNA and that CpG islands remain mostly unmethylated, recent studies
have shown methylation of CpG islands in the promoters of important developmental genes
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such as Hox genes (Auclair and Weber, 2012). Like the Hox genes, Lhx3 is a developmental
gene encoding a homeodomain transcription factor, but the role of DNA methylation in
expression of the Lhx3 gene has yet to be characterized. To investigate the effects of
methylation on Lhx3 gene transcription, we examined the methylation status of Lhx3
promoters in the mouse pituitary Pit-1/0 cell line. We describe the patterns of DNA
methylation of the Lhx3 promoters, examine the effects of methylation and histone
deacetylase (HDAC) inhibitors on Lhx3 gene expression and identify an interaction between
the Lhx3 promoters and MeCP2 in the mouse pituitary Pit-1/0 cell line. Understanding the
mechanisms involved in Lhx3 gene regulation will be important to the improved diagnosis
and treatment of LHX3 gene–associated diseases.
2. Materials and Methods
2.1. Cell Culture
Mouse Pit-1/0 and Pit-1/Triple cells (Sizova et al., 2010) were a generous gift from Dr. R.
Day (Indiana University; with permission from Dr. Stephen Liebhaber, University of
Pennsylvania) and were maintained in Hyclone Dulbecco’s Modified Eagle’s Media/Ham’s
Nutrient Mixture F-12 (1:1) with 2.5 mM L-glutamine (Hyclone, Logan, UT) supplemented
with 10% heat inactivated fetal bovine serum (Biowest, Nuaillé, France) and antibiotic-
antimycotic (Invitrogen, Gran Island, NY). The cells were grown at 37°C in humidified 5%
CO2 atmosphere. Cells (1 × 106 cells/10 cm) were plated and 24 hours later treated with 2.5
µM 5’-aza-2’-deoxycytidine (5-aza-dc; Sigma-Aldrich, St. Louis, MO) or 2.0 µM 5-aza-dc
plus 100 nM Trichostatin A (TSA; Sigma-Aldrich) in media containing 10% FBS. Cells
treated with 2.0 µM 5aza-dc plus 100 nM TSA were harvested 24 hours after treatment,
while cells treated with only 2 µM 5-aza-dc were harvested 48 hours after treatment. Control
plates were treated with DMSO as vehicle.
2.2 Bioinformatic Analysis
EMBOSS CpGPlot (http://www.ebi.ac.uk/Tools/emboss/cpgplot/) was used to predict
potential CpG islands in the mouse and human Lhx3/LHX3 genes. Gene sequences including
3.5 kb upstream and 8 kb downstream of both mouse and human Lhx3 genes (UCSC
Genome Bioinformatics; http://genome.ucsc.edu/) were used as inputs in CpG Plot. The
minimum length of the reported CG-rich region was 200 bp. The observed to expected ratio
of C plus G to CpG in a set of 10 windows required before a CpG island is reported was 0.6.
2.3. Bisulfite Genomic Sequencing
Genomic DNA was isolated from treated and untreated Pit-1/0 cells and Pit-1/Triple cells
using a PureLink™ Genomic DNA Mini Kit (Invitrogen, Carlsbad, CA) according to the
manufacturer’s protocol. The bisulfite conversion was carried out with 500 ng of input
genomic DNA with the use of EZ DNA Methylation-Gold Kit™ (Zymo Research Corp.
Orange, CA) following the manufacturer’s protocol. The bisulfite converted DNA was
amplified by the PCR using the Fast Start High Fidelity PCR System (Roche, Mannheim,
Germany) with specific primers to the Lhx3a and Lhx3b promoters. Primers designed using
the MethPrimer software (http:/ww.urogene.org/methprimer/) were as follows: mouse Lhx3a
promoter forward, 5’-ggaaggttagagaaaaggttattt-3; Lhx3a promoter reverse, 5’-
aaaaaacaaaaactccaaaaacac-3’; Lhx3b promoter forward, 5’-gtatttgtaggaagttttgagtggtatt-3’;
Lhx3b promoter reverse, 5’-ccctaaacttcccctaaatctaac-3’. A ‘hot’ start PCR was performed by
initially heating the reaction to 95°C for 2 min. prior to the addition of enzyme. The reaction
then underwent 40 cycles of 95°C for 2 min, 59°C for 30 sec, 72°C for 1 min., and a final
extension time of 7 min. The PCR products were gel purified using Qiaquick™ gel
extraction kit (Qiagen, Valencia, CA), then cloned into pCR-4 TOPO vector using a
TOPO™ TA Cloning kit (Invitrogen, Grand Island, NY). Plasmid DNA from at least 14
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unique colonies per group was prepared using PureLink™ Quick Plasmid Miniprep
(Invitrogen) and sequenced (ACGT Inc., Wheeling, IL) using an M13 Forward (−20)
universal primer.
2.4. RNA isolation and Reverse Transcription
Pit-1/0 cells (1×106 cells/10 cm plate) and Pit-1/Triple cells (1×106cells/10cm plate) were
plated and total RNA was harvested 24 hours later using an RNAeasy Mini Kit (Qiagen,
Hilden, Germany) following the manufacturer’s protocol. Complementary DNA (cDNA)
was synthesized from 1 µg of total RNA using a High Capacity Reverse Transcription kit
(Applied Biosystems, Grand Island, NY) according to the manufacturer’s protocol. The
cDNA was used as a template for PCR reactions performed with GoTaq Green Master Mix
(Promega, Madison, WI). Primers used were as follows: mLhx3a forward, 5'-
aaccactggattagtgactg-3'; mLhx3b forward, 5'-gaagttcagggtcggaggg-3'; mLhx3a/b reverse, 5'-
tggtcacagcctgcacacat-3' β-actin forward, 5'-ctacaatgagctgcgtgtgg-3'; β-actin reverse, 5'-
tagctcttctccagggagga-3'. The PCR parameters were as follows: 95°C for 2 min, 40 cycles of
95°C 30 sec, 58°C 1 min, 72°C 1 min, and a final extension time of 72°C for 7 min. The
PCR products were separated using 10% acrylamide/TBE electrophoresis gels (Biorad,
Hercules, CA).
2.5. Protein Isolation and Western Blotting
Whole cell protein extracts of Pit-1/0 cells (1×107 cells/15 cm plate) and Pit-1/Triple cells
(1×107 cells/15 cm) were isolated for western blotting. Cells were harvested in RIPA lysis
buffer (150 mM NaCl, 2 mM EDTA, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 0.01
sodium phosphate, pH 7.2, 50 mM NaFl) plus one Complete Mini protease inhibitor cocktail
tablet (Roche). BCA™ Protein Assay kit (Thermo Scientific, Rockford, IL) was used to
determine protein concentration, according to the manufacture’s protocol. The harvested
protein (25 µg) was separated on a 12% acrylamide gel and immunoblotted to check
expression of LHX3 and MeCP2. Protein was transferred to PVDF membranes and
incubated with anti-LHX3 (Chemicon, Temecula, CA; 1:2,500) or anti-MeCP2 primary
antibodies (Abcam, Cambridge, MA; 2 µg/µl) in TBST (154 mM NaCl, 52 mM Tris, 1%
Tween 20) overnight at 4°C. The membrane was washed and then incubated with the
appropriate peroxidase-conjugated secondary antibody (1:25,000) in TBST for 1 hour. The
membrane was incubated in SuperSignal West Dura Extended Duration Substrate (Thermo
Scientific, Rockford, IL) and then documented using a G-Box Imaging System (Syngene,
Frederick, MD).
2.6. Chromatin Immunoprecipitation Assays
Pit-1/0 chromatin was isolated for chromatin immunoprecipitation (ChIP) analyses.
Approximately 1–2 × 107 Pit-1/0 cells were grown in 15 cm culture dishes and treated with
2.5 µM 5-aza-dc, 100 nM TSA, 2.0 µM 5-aza-dc plus 100 nM TSA or DMSO vehicle.
Twenty-four hours after treatment, chromatin was isolated from the 100 nM TSA cells and
2.0 µM 5-aza-dc plus 100 nM TSA treated cells. Cells from the 2.5 µM 5-aza-dc only
treatment were harvested 48 hours post treatment. The ChIP assay was carried out with EZ
ChIP Kit (Millipore, Billerica, MA) following the manufacturer’s protocol. DNA shearing
efficiency was determined via electrophoresis. After the crosslinks were reversed lysates
were sheared in a water bath sonicator (Diagenode, Denville, NJ) with 30 × 30 seconds
sonication, 30 seconds off. The sheared samples were separated on 1.5% agarose gel to
check for DNA fragmentation below 1 kb. Pit-1/0 chromatin was mixed with cold dilution
buffer and protease inhibitor cocktail. The samples were pre-cleared for 1 hour with Salmon
Sperm-Blocked Protein A agarose beads and centrifuged at 10K for 30 seconds. An input
control sample (1%) was saved for downstream PCR. The supernatants were incubated with
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5 µg of antibody overnight with gentle shaking. The following antibodies were used: anti-
acetyl Histone 3 (Millipore), MeCP2 (Millipore), RNA Polymerase II (Millipore) as a
positive control, and rabbit IgG as a negative control. Then, protein A agarose beads were
added and incubated at 4°C for 2–4 hours. According to the manufacturer’s instructions, the
beads were washed with 1 mL of each solution in the order listed for 5 minutes at 4°C: low
salt buffer, high salt buffer, LiCl buffer and TE.
The relative abundance of regions of interest in precipitated DNA was measured by
quantitative (q) PCR (ABI 7900 PRISM, Applied Biosystems, Foster City, CA) using SYBR
green (Roche, Indianapolis, IN). The isolated ChIP input DNA was diluted 1:10 and primers
to the Lhx3 promoters were as follows: Lhx3a forward, 5'-tgaaagaggtccagcacttcc-3'; Lhx3a
reverse, 5'-tggcaatcgagttctgcttc-3'; Lhx3b forward, 5'-tctgtaggaagccttgagtgg-3’; Lhx3b
reverse, 5'-cgtctggcttgcacttcc-3'. The PCR parameters were as follows: 95°C 15 min. for one
cycle, 95°C 15 sec, 60°C 60 sec for 40 cycles and 95°C 15 sec, 60°C 1 min., 95°C 15 sec for
one cycle. Fold enrichment was calculated using the following formula:
2^[Ct (IgG)−Ct(experimental)]. The Student’s t-test was used to determine differences between
groups. Values were considered significantly different when P < 0.05.
3. Results
3.1. Analysis of Lhx3 mRNA and protein expression
Recently, mouse cell lines representing different stages of anterior pituitary cell
development have been generated using pituitary promoters to target immortalizing genes in
transgenic animals (Sizova et al., 2010). Of these, the Pit-1/0 and Pit-1/Triple lines represent
earlier and later stages, respectively. Unfortunately, similar reagents modeling human
pituitary cell types are not available. To examine whether the Lhx3a and Lhx3b mRNAs are
expressed in Pit-1/0 and Pit-1/Triple cells, total RNA was obtained and Lhx3a, Lhx3b and
actin (positive control) transcripts were detected by RT-PCR. The Pit-1/Triple cells
expressed both Lhx3a and Lhx3b, while neither transcript was expressed in the Pit-1/0 cells
(Figure 1A). Correspondingly, LHX3 protein was detected in the Pit-1/Triple cells, but was
not observed in the Pit-1/0 cells using western assays of whole cell protein extracts (Figure
1B).
3.2. Identification and investigation of methylated regions in Lhx3 promoters
To determine if methylation might play a role in Lhx3 gene expression, bioinformatics was
used to identify possible CpG rich regions in the Lhx3 promoters. The EMBOSS CpGPlot
online tool predicted a CpG-rich region encompassing the Lhx3b promoter of both the
mouse and human genes. A CpG-rich region also was noted in the human LHX3a promoter,
but the corresponding region in the mouse Lhx3a gene promoter does not have quite as high
a CpG density. To further probe the role of methylation of the two mouse Lhx3 promoters, a
333 bp region of the mouse Lhx3a promoter (−166 to +166 relative to the major
transcription start site) containing SP1 binding sites and 15 CG sites was identified for
further analysis (Figure 2A). Similarly, the CpG-rich region corresponding to the mouse
Lhx3b promoter was included in a 321 bp region (−235 to +85) containing 30 CG sites and
SP1 binding sites A (Figure 3A).
In order to characterize the methylation status of the Lhx3 promoters in the Pit-1/0 and Pit-1/
Triple cell lines, genomic DNA was subjected to bisulfite conversion and sequencing.
During bisulfite conversion, cytosines (C) are converted to thymines (T), but 5-
methylcytosines remain unaltered. Bisulfite sequencing data from a series of individual
DNA clones extracted from Pit-1/0 cells demonstrated that the Lhx3b promoter is highly
methylated at specific sites, while the Lhx3a promoter is less methylated (Figures 3B and
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2B, respectively). The transcription start site region of the Lhx3b promoter has low DNA
methylation (Figure 3B). Pit-1/Triple cells were also subjected to bisulfite sequencing
analysis (Figure 4). The Lhx3b promoter of the Pit-1/Triple cells is somewhat less
methylated than the Lhx3b promoter in the Pit-1/0 cells, especially in the central section of
the assayed region.
3.3. 5-Aza-2’-deoxycytidine induces Lhx3 expression
To determine whether Lhx3 promoter methylation could be linked to the lack of detectable
expression in Pit-1/0 cells, the cells were treated with the 5-Aza-2’-deoxycytidine (5-aza-dc)
demethylating reagent. Lhx3a expression was induced 24 hours after 2.5 µM 5-aza-dc
treatment, and both transcripts were expressed 48 hours post treatment (Figure 5A, B),
suggesting that methylation plays a role in Lhx3 expression. Bisulfite sequencing of
individual DNA clones from Pit-1/0 cells treated with 5-aza-dc for 48 hours (higher level of
Lhx3 transcripts) showed modest decreases in methylation of both the Lhx3a and Lhx3b
promoters (Figure 5C). The CpG sites at +12 and +17 of the Lhx3b promoter were not as
affected by the treatment, with 57% and 50% of the clones methylated at the sites,
respectively.
3.4. Trichostatin A and 5-aza-dc treatment induce Lhx3 expression
DNA methylation has been shown to recruit chromatin modifying proteins to modulate gene
expression (reviewed in Berger, 2002; Cosgrove and Wolberger, 2005; Vaissiere et al.,
2008; Bogdanovic and Veenstra, 2009; Zhang and Ho, 2011; Buck-Koehntop and Defossez,
2013). To investigate whether the interaction between DNA methylation and chromatin
modification can alter Lhx3 expression, Pit-1/0 cells were treated with both 5-aza-dc and the
HDAC inhibitor, trichostatin A (TSA). The optimal dosage of the dual treatment that did not
lead to cell death was determined to be 2.0 µM 5-aza-dc plus 100 nM TSA for 24 hours. The
combined treatment induced expression of both Lhx3 transcripts (Figure 6A). Bisulfite
sequencing of the Pit-1/0 cells treated with 5-aza-dc plus TSA indicated some decreased
methylation of both Lhx3 promoters (Figure 6B, C). Treatment with TSA plus 5-aza-dc
decreased methylation at the CpG sites +12, +17, +22, +27, +38 and +52 of the Lhx3b
promoter compared to the bisulfite sequencing of untreated Pit-1/0 cells. In dual treated
cells, bisulfite sequencing revealed that although methylation decreased at CpG sites −206
and −197 of the Lhx3b promoter, 50% or higher of clones still remained methylated after
treatment.
3.5. The MeCP2 methyl-binding protein occupies the Lhx3 promoter
Methyl-CpG-binding proteins bind methylated DNA to regulate gene transcription
(Robertson and Jones, 2000; Bogdanovic and Veenstra, 2009). MeCP2, a member of the
methyl-binding domain (MBD) family of proteins is a regulator of global de novo
methylation and has been shown to bind the pituitary pro-opiomelanocortin (Pomc) gene
promoter (Tao et al., 2009). We determined if MeCP2 and its related protein family
member, MBD2 were expressed in the Pit-1/0 pituitary cell line. Whole cell protein extracts
from Pit-1/0 cells were probed by western analyses using antibodies recognizing MeCP2,
MBD2 and GAPDH (positive control). Both MeCP2 and MBD2 protein were detected in the
Pit-1/0 cells (Figure 7A). Because treatment with the demethylating reagent, 5-aza-dc and
the HDAC inhibitor, TSA induced Lhx3 expression, we further investigated how treatment
with 5-aza-dc and 5-aza-dc plus TSA might alter Lhx3 promoter occupation by MeCP2 and
acetylated histone 3 (acH3). Acetylation of histones relaxes the chromatin structure and
histone acetylation is often used as a marker of gene activation (Berger, 2002). To examine
the effects of the inhibitors, chromatin immunoprecipitation (ChIP) assays were performed
in treated and untreated Pit-1/0 cells with antibodies to MeCP2, MBD2, acH3 and IgG
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(negative control) and primers to the Lhx3 promoters. The 5-aza-dc plus TSA and control
plates were harvested 24 hours post treatment and the 5-aza-dc treated cells were harvested
for chromatin 48 hours post treatment to capture maximized Lhx3 expression in the cells.
Analysis of the ChIP assay with Pit-1/0 cells indicated detection of acH3 and MeCP2 but not
notable MBD2 at the Lhx3 promoters (Figure 7B, C). Pit-1/0 cells treated with 5-aza-dc
showed an approximately two-fold decrease in acH3 enrichment and a modest decrease in
MeCP2 enrichment at the Lhx3a promoter (Figure 7B). For the Lhx3b promoter, 5-aza-dc
treatment led to a modest increase in acH3 enrichment and no change in MeCP2 enrichment
(Figure 7C). Analysis of ChIP assays with Pit-1/0 cells treated with 5-aza-dc plus TSA
indicated an increase in acH3 enrichment and a decrease in MeCP2 enrichment at the Lhx3a
promoter region (Figure 7B). Enrichment of acH3 at the Lhx3b promoter of the dual treated
cells notably increased, while there was no major change in MeCP2 enrichment of the Lhx3b
promoter (Figure 7C).
4. Discussion
DNA methylation has roles in a variety of cellular processes including transcriptional
regulation (Bird, 1992). Methylation occurs at CpG sites so GC-rich DNA regions can be
modified by DNA methylation (Smith and Meissner, 2013). The Lhx3 gene has two TATA-
less, GC-rich promoters (Yaden et al., 2006) and recent studies have demonstrated
methylated CpG islands in the promoters of developmental genes such as the Hox genes
(Auclair and Weber, 2012) suggesting the hypothesis that DNA methylation patterns may
affect Lhx3 gene expression. In this study, we describe the first investigation of the role of
DNA methylation in Lhx3 gene transcription.
The recently established murine Pit-1/0 and Pit-1/Triple cell lines represent different phases
of Pit-1-dependent cell differentiation in mouse anterior pituitary development (Sizova et al.,
2010). The Pit-1 transcription factor is critical for differentiation of the somatotropes,
lactotropes and thyrotrope cells of the anterior pituitary, and it synergistically interacts with
LHX3 to regulate pituitary genes, such as Prl (Savage et al., 2003). In the Pit-1/0 cells, the
Pit-1 gene is expressed, but the cells fail to express Pit-1-dependent hormones. The Pit-1/
Triple cells represent a later phase of differentiation and express the Pit-1 gene and GH,
PRL and TSHβ. The expression of the Lhx3 gene in these “Pit-1 lineage” cell lines had yet
to be determined. In this study, we found that whereas the Pit-1/0 cells do not express either
the Lhx3 gene or the LHX3 protein, the Pit-1/Triple cells produce LHX3. Therefore, the
Pit-1/0 cells represent a valuable model investigate the role of DNA methylation in Lhx3
gene expression.
Bioinformatics was used to identify CpG-rich regions in the mouse and human Lhx3
promoters. Bisulfite sequencing was performed in both the Pit-1/0 and Pit-1/Triple cell line.
The Pit-1/Triple cells are less methylated in the Lhx3b promoter region compared to the
Pit-1/0 cells. Although the transcription start site (TSS) of each promoter in the Pit-1/0 cells
is nearly devoid of methylation, surrounding sites within each promoter region are
methylated. Since promoters are regions of regulatory control, it is possible that the
surrounding methylated sites help coordinate protein-DNA interactions, and subsequent
activities to regulate gene expression. Also, the DNA methylation pattern at or near the TSS
may be determined by the local chromatin conformation (or conversely, such that DNA
methylation dictates chromatin conformation), contributing to a pattern conducive for gene
control (Cedar and Bergman, 2009).
CpG-rich regions in the Lhx3a and Lhx3b promoters contained previously identified SP1
binding sites (Yaden et al., 2006). SP1 has established roles in basal transcriptional activity
of genes with GC-rich promoters, and SP1 binding sites have been noted as sites of DNA
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methylation control in some cases (Li et al., 2004). Although there are multiple studies
examining the methylation status of SP1 binding sites, the findings are conflicting. Some
studies have found that methylation of SP1 binding sites prevents its binding and subsequent
gene activation, while others have shown that methylation of SP1 binding sites does not alter
its binding (e.g. Harrington et al., 1988; Holler et al., 1988; Mancini et al., 1999; Butta et al.,
2006; Douet et al., 2007). We found that there were no obvious differences in the DNA
methylation patterns associated with the SP1 binding sites between the Pit-1/0 cell lines,
which do not express the Lhx3 gene and the Pit-1/Triple cell line that does express the Lhx3
gene. These findings suggest that the methylation status of the promoter SP1 sites is not
critical for the transcriptional status of the Lhx3 gene.
To further clarify how DNA methylation may impact the expression of the Lhx3 gene, we
treated the cells with the demethylating reagent, 5-aza-dc. This reagent inhibits DNA
methyltransferase activity causing hypomethylation. Treatment with 5-aza-dc induced
expression of both Lhx3 mRNA transcripts in the Pit-1/0 cells, with increased expression
correlating with longer exposure to the reagent. DNA samples from treated cells were
subjected to bisulfite sequencing, and the results showed some decreases in methylation at
both the Lhx3a and the Lhx3b promoter CpG-rich regions. Together, this data suggests that
methylation may be part of Lhx3 gene inactivity in the Pit-1/0 cells. To our knowledge, this
is the first report of such an activation of Lhx3 gene expression in a model system.
Acetylation is a well characterized post translational histone modification that is often a
marker of gene activation (reviewed in Berger, 2002). The addition of an acetyl group is
catalyzed by histone acetyl transferases (HATs), whereas the removal of acetyl groups is
catalyzed by histone deacetylases (HDACs). Interestingly, treatment of Pit-1/0 cells with
both 5-aza-dc and the HDAC inhibitor TSA led to a rapid induction of Lhx3 mRNA
expression, suggesting possible cross-talk between the DNA methylation and chromatin
microenvironment. Similar results have been seen in other studies, involving 5-aza-dc and
TSA treatment to induce gene activity. For example, 5-aza-dc weakly activated expression
of the retinoic acid receptor and estrogen receptor α; genes in MDA-MB-231 breast cancer
carcinoma cells, while the combination treatment of 5-aza-dc plus TSA resulted in greater
activation of both genes (Bovenzi and Momparler, 2001).
Methyl-CpG binding proteins have been shown to recruit histone modifiers to modulate
transcription (Nan et al., 1998; Jones and Liang, 2009), so communication between methyl-
CpG binding proteins and chromatin modifiers may influence Lhx3 mRNA expression. The
methyl-binding protein, MeCP2 has been shown to bind the pituitary proopiomelanocortin
(Pomc) gene promoter (Tao et al., 2009) and we therefore hypothesized that it may be
similarly associated with the methylated Lhx3 promoters. ChIP assay analysis indicated that
MeCP2 is associated with both Lhx3 promoters in Pit-1/0 cells. Studies in Xenopus and mice
have demonstrated that MeCP2 interacts with Sin3 and histone deacetylase to trigger
deacetylation of histones (Jones et al., 1998; Nan et al., 1998). Another study showed that
MeCP2 recruited the mSin3a-HDAC1 complex to repress transcription of the brain-derived
neurotrophic factor promoter in cortical cells (Chen et al., 2003; Martinowich et al., 2003;
Klose and Bird, 2004). Therefore, we performed ChIP assays to investigate how inhibiting
HDACs and/or blocking methylation may alter MeCP2 and acetylated histone H3 (acH3)
occupation of the Lhx3 promoters. Interestingly, the treatments resulted in different effects
on each Lhx3 promoter. Analysis of the ChIP assay with Pit-1/0 cells treated with 5-aza-dc
showed only a very slight decrease in both acH3 occupation and MeCP2 occupation of the
Lhx3a promoter. A decrease is MeCP2 occupation was expected, since the reagent blocks
methylation and thereby potentially prevents MeCP2 from binding the methylated DNA.
The decrease in acH3 occupation of the Lhx3a promoter with 5-aza-dc treatment may
suggest potential cross-talk between chromatin status and DNA methylation. One possible
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explanation for the decrease in acH3 occupation of the promoter is that MeCP2 also
interacts with chromatin modifying proteins to activate genes (Jones et al., 1998; Nan et al.,
1998; Lunyak et al., 2002; Chen et al., 2013). For example, a study showed the MeCP2
recruits CREB1 to activate the murine neuronal glucose transporter isoform 3 (glut3) gene
in murine neurons (Chen et al., 2013). Therefore, blocking methylation with 5-aza-dc may
prevent MeCP2 from binding and recruiting other proteins that could potentially increase or
maintain basal histone acetylation at the promoter.
At the Lhx3b promoter, 5-aza-dc treatment led to a slight increase in acH3 occupation and
no change in MeCP2 occupation compared to untreated cells. Because MeCP2 recruits
HDACs, blocking methylation may prevent binding of MeCP2 to methylated DNA and
subsequent recruitment of HDACs to histones. The absence of recruited HDACs to histones
may translate to a decrease in histone deacetylation and possibly an increase in acetylation
of histone H3. The lack of change in Lhx3b promoter occupation by MeCP2 may be due to
the fact that some sites still remain methylated in the Lhx3b promoter after treatment and
therefore facilitate the binding of MeCP2 binding to the promoter. Additionally, the
resolution of the ChIP assay is limited by sonication of DNA fragments less than 1 kB so
precise resolution of changes in MeCP2 occupation may be challenging; nonetheless, the
examined sequence is within a key regulatory region of the Lhx3 gene.
Unlike ChIP assays performed with the 5-aza-dc treatment, analysis of ChIP assays
performed with Pit-1/0 cells treated with 5-aza-dc plus TSA indicated an increase in acH3
occupation and a decrease in MeCP2 occupation at the Lhx3a promoter region. These results
suggest cross-talk and possible synergy between methyl-binding proteins and chromatin
modifying proteins in regulating gene transcription, which has been seen in other studies
(Jones et al., 1998; Nan et al., 1998; Klose and Bird, 2004). An increase in occupation of
acH3 at the Lhx3b promoter resulted from the 5-aza-dc plus TSA treatment, while there was
no change in MeCP2 occupation of the Lhx3b promoter, compared to untreated cells. Again,
the lack of change in MeCP2 occupation may be due to the remaining methylated sites after
treatment.
Transcription is a dynamic process. Modifying epigenetic marks of the genes in a cell by
treatment with HDAC inhibitors and/or demethylating reagents may alter the temporal
expression of some genes, which in turn may result in downstream changes to both protein-
protein interactions and protein-DNA interactions. Therefore, expression of the Lhx3 gene
induced by treatment with the HDAC inhibitor and/or the demethylating reagent is most
likely the result of both direct and indirect effects. The change in methylation patterns after
treatment (demonstrated by the Lhx3 bisulfite sequencing) and the subsequent induction of
the Lhx3 gene suggest some roles for direct effects, but it should be noted that other
unassayed regions of the gene also likely contribute to its expression as well. Furthermore,
the transcription of upstream genes that regulate Lhx3, as well as chromatin conformation
may have been altered by the inhibitor treatment, contributing to the indirect induction of the
Lhx3 gene.
In future studies it would be interesting to examine the role of methylation in the human
LHX3 gene, including testing whether epigenetic mechanisms play a role in the actions of
the distal enhancer that is located downstream of the gene and has roles in pituitary and
nervous system expression of LHX3 (Mullen et al., 2012). However, the 3′ pituitary/neural
enhancer region has very few CpG sites in the “R3” region that is the critical cis element for
pituitary expression making such a mechanism perhaps less likely at least in cells such as
those tested here. Similarly, it will be interesting to examine whether there is interplay
between LHX3 gene regulation and the actions of the Inhibitor of Histone Acetyltransferase
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complex (INHAT) proteins that were recently suggested to be part of the mechanism of
action of LHX3 (Hunter et al., 2013).
Collectively, these findings implicate DNA methylation in the regulation of mouse Lhx3
gene transcription. We have shown that the demethylating reagent 5-aza-dc can induce Lhx3
gene activation both independently, and in combination with the HDAC inhibitor, TSA, in a
pituitary precursor cell suggesting possible crosstalk between DNA methylation and
chromatin modifiers. The methyl-binding protein, MeCP2 has been shown to occupy the
Lhx3 promoter in Pit-1/0 cells and it may function as either a transcriptional repressor or
activator, depending on the specific chromatin architecture. LHX3 plays a critical role in
pituitary development, and mutations in LHX3 lead to severe pediatric combined pituitary
hormone deficiency (CPHD) diseases. Characterization of the cellular processes that
influence LHX3/Lhx3 expression, including mechanisms such as DNA methylation are
critical to our understanding of pituitary organogenesis and disease.
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Highlights
• LHX3 is a transcription factor with critical roles in pituitary and nervous system
development.
• The role of DNA methylation in expression of the mouse Lhx3 transcription
factor gene was examined.
• Treatment of cultured Pit-1/0 pituitary cells with a demethylating reagent lead to
activation of the Lhx3 gene.
• DNA methylation levels of Lhx3 promoter regions in untreated and treated
Pit-1/0 cells were examined.
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Figure 1. Lhx3 mRNA and protein are expressed in mouse pituitary Pit-1/Triple but not Pit-1/0
cells
(A) Lhx3a or Lhx3b mRNA was amplified by RT-PCR in Pit-1/0 and Pit-0/Triple cells. Beta
actin primers were used in a positive control to test cDNA integrity. (B) Protein levels of
LHX3 were determined by western blotting of whole cell protein extracts of Pit-1/0 and
Pit-1/Triple cells. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibodies were
used as positive controls. Each experiment was performed three times with similar results.
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Figure 2. Lhx3a promoter and its methylation pattern
(A) The upper diagram represents the mouse Lhx3 gene, with black rectangles signifying
protein-coding exons and white areas denoting untranslated exonic regions. Two upstream
promoters (aP and bP) produce the Lhx3a and Lhx3b mRNAs. The lower diagram below
shows potential sites of methylation in the Lhx3a promoter, spanning from position −166 to
+166 with the major transcription start site (TSS) set to position 0. Each vertical black bar
indicates a CG base pair. The positions of SP1 binding sites (Yaden et al., 2006) are shown.
(B) The methylation pattern of the Lhx3a promoter in mouse pituitary Pit-1/0 cells was
determined by bisulfite sequencing (see materials and methods). Black boxes indicate
Malik and Rhodes Page 16
Gene. Author manuscript; available in PMC 2015 January 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
methylated CpGs and open boxes indicate non methylated CpGs. Horizontal rows in each
diagram represent individual sequenced clones from experiments. The overall percentage of
observed methylation at each position is noted.
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Figure 3. Lhx3b promoter and its methylation pattern
(A) The upper diagram represents the mouse Lhx3 gene, with black rectangles signifying
protein-coding exons and white areas denoting untranslated exonic regions. Two upstream
promoters (aP and bP) produce the Lhx3a and Lhx3b mRNAs. The diagram below shows
sites of potential methylation in the Lhx3b promoter, spanning from position −235 to +85
with the transcription start site (TSS) set at position 0. The positions of SP1 binding sites are
shown. (B) The methylation pattern of the Lhx3b promoter in mouse pituitary Pit-1/0 cells
was determined by bisulfite sequencing (materials and methods). Black boxes indicate
methylated CpGs and open boxes indicate non methylated CpGs.
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Figure 4. Lhx3 promoter methylation patterns in Pit-1/Triple cells
(A) The methylation pattern of the Lhx3a promoter in mouse pituitary Pit-1/Triple cells was
determined by bisulfite sequencing. Black boxes indicate methylated CpGs and open boxes
indicate non methylated CpGs. Horizontal rows in each diagram represent individual
sequenced clones from experiments. The overall percentage of observed methylation at each
position is noted. (B) The methylation pattern of the Lhx3b promoter in mouse pituitary
Pit-1/Triple cells.
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Figure 5. Lhx3 expression is activated in mouse pituitary Pit-1/0 cells after treatment with 5’-
aza-dc
Pit-1/0 cells were treated with 2.5 µM 5-aza-dc and RNA was harvested 24 hours (A) or 48
hours (B) after treatment and RT-PCR was performed. (C) Pit-1/0 cells were treated with
2.5 µM 5-aza-dc and genomic DNA was harvested for bisulfite conversion 48 hours post
treatment. The methylation patterns of the Lhx3a (top) and Lhx3b (bottom) promoters were
determined by bisulfite sequencing as described in the materials and methods. Black boxes
indicate methylated CpGs and open boxes indicate non methylated CpGs.
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Figure 6. Lhx3 expression after treatment with 5’-aza-dc plus TSA in Pit-1/0 cells
(A) Mouse pituitary Pit-1/0 cells were treated with 2.0 µM 5-aza-dc plus 100 nM TSA and
RNA was harvested 24 hours after treatment and RT-PCR was performed. (B), (C) Pit-1/0
cells were treated with 2.0 µM 5-aza-dc plus 100 nM TSA and genomic DNA was harvested
for bisulfite conversion analysis at 24 hours post treatment. The methylation pattern of the
Lhx3a (B) and Lhx3b (C) promoters were determined by bisulfite sequencing as described in
the materials and methods. Black boxes indicate methylated CpGs and open boxes indicate
non methylated CpGs.
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Figure 7. MeCP2 is associated with the Lhx3 gene in Pit-1/0 cells
(A) MeCP2 and MBD2 were detected in mouse pituitary Pit-1/0 cells by western blotting.
GAPDH was used as a positive control. Two independent cell extracts are shown. (B, C)
ChIP assays were carried out with chromatin from Pit-1/0 cells treated with 5-aza-dc, 5-aza-
dc plus TSA or DMSO (solvent control), using anti-MeCP2, anti-MBD2 (negative control),
anti-acetylated histone H3 (acH3) and IgG (negative control) antibodies and primers to the
Lhx3a and Lhx3b promoters. A representative experiment of three independent, biological
replicates is shown. Numbers indicate fold changes for untreated samples compared to IgG
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negative controls. Asterisks (*) indicate significant differences to IgG negative controls at
P<0.05.
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